# Phase 8 GRC/LGRC Causal Pathway Consolidation - Iteration 107

## Result

Iteration 107 passed as a stage-local source, test, and evidence crosswalk.
It did not alter runtime, tests, examples, telemetry, or the I106 registry.

```text
initial I105 families = 12
newly exposed I106 pathways = 5
final I106 pathways = 23
authority-bearing stage rows = 52
current-source targeted tests = 528 passed
current-source targeted subtests = 231 passed
bounded V1 exclusions = 21
runtime behavior changed = false
Iteration 108 ready = true
```

## Interpretation

Passing tests establish only the stage mechanics and claim ceilings recorded in
the crosswalk. They do not turn configured semantics into formed semantics,
producer-owned scheduling into native admission, diagnostics into constitutive
behavior, or restoration equality into semantic identity.

The I105-to-I106 migration is explicit. Historical artifacts retain their old
names; evidence from a split family is attached only to successor stages whose
behavior it actually exercised. Cross-cutting state, construction, telemetry,
and restoration contracts remain dependency evidence rather than pathway
implementation evidence.

## Evidence Ownership

```json
{
  "diagnostic": 8,
  "native": 5,
  "native_with_configured_semantics": 32,
  "producer": 4,
  "utility": 3
}
```

## Artifacts

- `specs/grc-lgrc-causal-pathway-evidence-crosswalk.json`
- `implementation/investigations/causal-pathway-consolidation/Phase-8-GRCLGRC-CausalPathwayConsolidationIteration107TestExecution.json`
- `implementation/investigations/causal-pathway-consolidation/Phase-8-GRCLGRC-CausalPathwayConsolidationIteration107.json`
- `implementation/investigations/causal-pathway-consolidation/Phase-8-GRCLGRC-CausalPathwayConsolidationIteration107ArtifactFreeze.json`

## Remaining Boundary

Iteration 107 establishes evidence attachment, not composition. Iteration 108
must still test directional compatibility, retained identity, authority transfer,
adapter ownership, information loss, and blocked relabels for representative
pathway compositions.
